

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

NCT06106672

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	COUR Pharmaceutical Development Company, Inc.
Enrollment	54 participants

Key Eligibility Criteria

Inclusion (12)

- Subjects who are willing and able to provide Institutional Review Board (IRB) approved written informed consent and privacy language as per national regulations.
- Men and non-pregnant women, ages 18-75 years inclusive.
- Female subjects of childbearing potential must agree not to become pregnant during the clinical study, have a negative pregnancy test at the Screening Visit, and agree to one of the following:
- Use two highly effective forms of birth control starting at initial screening and continuing throughout the study duration.
- Practice abstinence starting at initial screening and continuing throughout the study duration.

... and 7 more (see full listing online)

Exclusion (27)

- Subjects with a Myasthenia Gravis Foundation of America Clinical Classification Class I or V.
- Subjects with a history of cerebrovascular accident in the past 12 months.
- Subjects with MG-ADL Score ≤ 6 at Screen or Subjects with MG-ADL Score ≤ 6 at Screen with $\geq 50\%$ of the score derived from non-ocular symptoms.
- Subjects with QMG Score ≤ 11 at Screen.
- Subjects who have used the following medications:

... and 22 more (see full listing online)

Locations (17 total)

Barrow Neurological Institute, Phoenix, Arizona, United States
Neuromuscular Clinic and Research Center, Phoenix, Arizona, United States
Infusion for Health, Brea, California, United States

... and 14 more locations